- Home
- Blogs
France: Extension of framework agreement between French Pharmaceutical Companies Association and Economic Committee for Health Products
Browse this blog post
Related news and insights
Blog Post: 28 November 2022
Blog Post: 27 October 2022
Non-binding opinion of the Enlarged Board of Appeal issued in the G 2/21 referral on "plausibility"
Blog Post: 06 April 2021
France – Mediator scandal: Servier laboratories convicted of aggravated deception and manslaughter
Blog Post: 25 March 2021
New pricing agreement in France includes provisions on biosimilars pricing for the first time
At the end of the Conventional Policy Steering Committee held on 23 July 2020, the French Pharmaceutical Companies Association (Leem) and the French Economic Committee for Health Products (CEPS) agreed to an extension of their Framework Agreement, which is the reference framework for fixing and regulating medicines pricing in France.
The agreement, which would have otherwise expired on 31 July 2020, is now valid until 31 December 2020.